AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04450602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR Shampoo
Description: ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR Conditioner
Description: ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR Hair Follicle Serum (Nutriment)
Description: ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)
Study NCT04450602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)
Study NCT04450602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Shampoo
Description: Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Conditioner
Description: Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hair Follicle Serum (Nutriment)
Description: Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)
Study NCT03084666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer ATS tourniquet system
Description: The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
Study NCT01656889 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: (fibrinogen solution \& thrombin solution without cells)
Study NCT01499082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
Study NCT01499082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Study NCT03442712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupressure plus smartphone App
Description: Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
Study NCT03442712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupressure
Description: The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
Study NCT02089256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
Study NCT04389450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
Study NCT04389450 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection
Study NCT02525965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide resection margin >1cm
Description: Surgical removal of lesions choosing the method of wide resection margin >1cm
Study NCT02525965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Narrow resection margin <1cm
Description: Surgical removal of lesions choosing the method of wide resection margin \<1cm
Study NCT02522936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotene oral spray
Description: Biotene oral spray will be provided to participants.
Study NCT02254226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Diskus low
Study NCT02254226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Diskus high
Study NCT02254226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI low
Study NCT02254226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol MDI high
Study NCT00633464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria.
Study NCT00633464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone + cetuximab
Description: Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria.
Study NCT02478060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch-SPIRE
Study NCT03030222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg Tab
Description: Empagliflozin 10 mg Tab
Study NCT03030222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Empagliflozin matching placebo
Study NCT01563536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: Tablet
Study NCT01563536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: Tablet
Study NCT01563536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet
Study NCT01563536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Capsule
Study NCT01563536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT01356355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbmed plus
Description: one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
Study NCT01356355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice a day daily till ureteral stent in situ
Study NCT01356355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: One capsule twice a day daily till ureteral stent in situ
Study NCT01825681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect
Description: Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
Study NCT02510430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Patterning Sitting Time Group
Description: This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
Study NCT02510430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing Sitting Time Group
Description: This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
Study NCT02510430 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
Study NCT00753792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: methylprednisolone 1.000 mg/day intravenous administration during three days
Study NCT00753792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone 1.250 mg/day orally administered during three days
Study NCT00753792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
Study NCT00753792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
Study NCT02674893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02674893 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation alone
Study NCT02674893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation alone
Study NCT03580889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Comparison between atropine, glycopyrrolate and Normal Saline
Study NCT03580889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Comparison between glycopyrrolate, atropine and Normal saline
Study NCT03580889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Comparison between Normal saline, atropine and glycopyrrolate
Study NCT00844025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Description: Medication review, medication reconciliation, and pharmacotherapy recommendation.
Study NCT00696410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
Study NCT03249051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry
Description: Energy need is being determined using indirect Calorimetry
Study NCT02478060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02809183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension
Study NCT02809183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: oral suspension
Study NCT03315975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Description: One dose of quadrivalent inactivated influenza vaccine
Study NCT04188977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Practice
Description: OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
Study NCT04188977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation
Description: Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
Study NCT04058353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: FDC tablet for oral administration.
Study NCT04058353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Mono-tablet for oral administration.
Study NCT04058353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Mono-tablet for oral administration.
Study NCT04058353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study NCT03530592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seated Ankle Robot Training
Description: This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
Study NCT02076724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biological mesh
Study NCT02434380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Euro D
Description: Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
Study NCT02434380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Euro D
Description: Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
Study NCT02226913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: 2% lidocaine with 1:80,000 epinephrine
Study NCT02226913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: 2% lidocaine with 1:80,000 epinephrine
Study NCT02226913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: 8.4% sodium bicarbonate
Study NCT02226913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: sterile distilled water (Samen Pharmaceutical Co, Iran)
Study NCT02658864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lafutidine
Description: comparison of different doses, sex and medication conditions
Study NCT02118129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an educational video
Study NCT02118129 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: wait listed
Study NCT02417818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)
Study NCT02417818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)
Study NCT02417818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)
Study NCT02417818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)
Study NCT01420848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy
Description: Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
Study NCT01420848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
Study NCT03951454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conexiones
Description: 5 Conexiones telephone sessions
Study NCT03951454 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Taking Time
Description: 1 Taking Time telephone session
Study NCT00790283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTCA with stent implantation
Description: Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure.
Study NCT00790283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA with stent implantation
Description: Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure.
Study NCT01381796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NP101
Description: comparison of NP101 with minor patch modifications
Study NCT01381796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: comparison of NP101 with minor patch modifications
Study NCT01381796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan succinate
Description: tablet, 100 mg
Study NCT02365519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LME636 ophthalmic solution
Study NCT02365519 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LME636 Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT02291679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Study NCT02291679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo